Adalimumab significantly reduces inflammation and serum <scp>DKK</scp>‐1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis

Abstract

Our study found that adalimumab was highly effective in reducing inflammation in active AS patients, but it was accompanied by the formation of FDL in the lumbar spine and decrease in serum DKK-1 levels.